China has the largest cardiovascular disease patient population with an estimated 350 million patients. We are excited to have the opportunity to partner with leading biotech companies to bring innovative therapies to China. 

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiovascular disorder. Aficamten, a next-generation cardiac myosin inhibitor, is designed to reduce cardiac hypercontractility which underlies the pathophysiology of HCM. We believe that aficamten has the potential to significantly improve the current treatment status and have a meaningful impact for patients.

The prevalence of chronic heart failure has been rising in China, affecting more than 10 million patients. A large amount of HFrEF patients have signs and symptoms of worsening heart failure despite standard of care therapy. We look forward to engaging the NMPA and medical community regarding omecamtiv mecarbil and to bringing this potential new medicine to Chinese patients soon.

There are approximate 3-6 million patients in China who suffer from Paroxysmal Supraventricular Tachycardia (PSVT) which has a material impact on their health and quality of life. Etripamil has the potential to change the treatment paradigm for PSVT and could serve as a meaningful new therapeutic option for patients.

Stimulating natural tear production may trigger a paradigm-shift in dry eye disease treatment, which affects more than 200 million people in China. Well designed mechanism to maintain the pupil size in its sweet spot, for an extended range of vision and a potentially better iris contour, may help huge population in their aging process.